Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020

DEER PARK, Ill., Feb. 27, 2020 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report fourth quarter and full year 2019 financial and operating results on Thursday, March 5, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (3:30 p.m. CT).

The live webcast can be accessed on the investors section of Eton’s website at https://ir.etonpharma.com/. The conference call can be accessed by dialing 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 5119269. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.

About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products. Eton is primarily focused on hospital injectable and pediatric oral liquid products. The company’s first commercial product, Biorphen, is the only FDA approved ready-to-use formulation of phenylephrine injection and was launched in December 2019. The company has an additional eight products under development, including three that are under review with the FDA.

Investor Contact:
David Krempa
[email protected]
847-805-1077